Literature DB >> 7774888

neu overexpression correlates with extent of disease in large cell ductal carcinoma in situ of the breast.

C R De Potter1, A M Schelfhout, P Verbeeck, S R Lakhani, R Brünken, C A Schroeter, J G Van den Tweel, A J Schauer, J P Sloane.   

Abstract

In a retrospective study of ductal carcinoma in situ (DCIS) of the breast, the expression of the neu oncogene was determined immunohistochemically in 76 women treated by local excision or mastectomy. The histopathological features, including the extent of the lesion, histological subtype, cell type, and number of mitoses, were related to neu overexpression. Immunopositivity was found only in DCIS of large cell type, where it correlated with extent of disease but not with mitotic rate. Our findings, together with previous experimental evidence, suggest that this relationship is a consequence of the effect of the neu protein on cell motility.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7774888     DOI: 10.1016/0046-8177(95)90163-9

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

1.  C-Erb-b2 oncogene expression in intraductal proliferative lesions of the breast.

Authors:  Filiz Eren; Zerrin Calay; Haydar Durak; Bülent Eren; Nil Comunoğlu; Ovgü Aydin
Journal:  Bosn J Basic Med Sci       Date:  2012-02       Impact factor: 3.363

Review 2.  The neu-protein and breast cancer.

Authors:  C R De Potter; A M Schelfhout
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

Review 3.  Biological features of premalignant disease in the human breast.

Authors:  D C Allred; S K Mohsin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

4.  Arecoline induced disruption of expression and localization of the tight junctional protein ZO-1 is dependent on the HER 2 expression in human endometrial Ishikawa cells.

Authors:  Sarbani Giri; Kevin M Poindexter; Shyam N Sundar; Gary L Firestone
Journal:  BMC Cell Biol       Date:  2010-07-06       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.